NicoleRaleigh said:Worth knowing that the injection site changes very little.
GFR trending upward on renal function — encouraging for those with mild CKD concerns:
Baseline eGFR: 72 → Month 6: 82 → Month 12: 87
The FLOW trial confirmed renal benefits of semaglutide: 24% reduction in kidney disease progression. My nephrologist is now actively recommending GLP-1 therapy for appropriate CKD patients. This could be a paradigm shift in nephrology.
NicoleRaleigh said:Worth knowing that the injection site changes very little.
No disagreement, though it depends on where somebody is starting from, and this thread has been assuming a starting point nobody stated.
NicoleRaleigh said:Worth knowing that the injection site changes very little.
Thank you — that is the clearest version of this I have read, and I have read a lot of them. Taking it to my next appointment.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsFrom the other side of the consultation, briefly. Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then measure again under the same conditions.
Dr.NephBHM_UK said:Order of operations matters more than any single choice here: establish a baseline, change one thing, wait long enough for it to express itself, then…
Same pattern here, and in the same order.